Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBAT 1: Vemurafenib and Aldesleukin in Melanoma
NCT01754376Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2013
- Primary completion
- Feb 2015
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, aldesleukin in melanoma, sponsored by Massachusetts General Hospital. Started Jan 2013; status: terminated.
02
Drugs
vemurafenibaldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01754376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01754376.